Search results
Showing 631 to 645 of 1259 results for pathway
Evidence-based recommendations on sparsentan (Filspari) for treating primary immunoglobulin A (IgA) nephropathy in adults.
Bladder EpiCheck for detecting bladder cancer recurrence (MIB293)
NICE has developed a medtech innovation briefing (MIB) on Bladder EpiCheck for detecting bladder cancer recurrence .
Dexcom G6 for real-time continuous glucose monitoring (MIB233)
NICE has developed a medtech innovation briefing (MIB) on Dexcom G6 for real-time continuous glucose monitoring .
NICE has developed a medtech innovation briefing (MIB) on Smart Peak Flow for monitoring asthma .
This guideline covers the components of a good experience of service use. It aims to make sure that all adults using NHS mental health services have the best possible experience of care.
Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)
NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .
This quality standard covers the management of Parkinson’s disease in adults. It does not include treatment of parkinsonism not caused by Parkinson’s disease. It describes high-quality care in priority areas for improvement.
View quality statements for QS164Show all sections
Sections for QS164
- Quality statements
- Quality statement 1: Point of contact with specialist services
- Quality statement 2: Information about impulse control disorders
- Quality statement 3: Referral to physiotherapy, occupational therapy or speech and language therapy
- Quality statement 4: Levodopa in hospital or a care home
- Quality statement 5: Access to clozapine for treating hallucinations and delusions
- About this quality standard
Evidence-based recommendations on galcanezumab (Emgality) for preventing migraine in adults.
Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma (TA462)
Evidence-based recommendations on nivolumab (Opdivo) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Andexanet alfa for reversing anticoagulation from apixaban or rivaroxaban (TA697)
Evidence-based recommendations on andexanet alfa (Ondexxya) for reversing anticoagulation form apixaban or rivaroxaban in adults with life-threatening or uncontrolled bleeding.
Brentuximab vedotin in combination for untreated systemic anaplastic large cell lymphoma (TA641)
Evidence-based recommendations on brentuximab vedotin (Adcetris) with cyclophosphamide, doxorubicin and prednisone for untreated systemic anaplastic large cell lymphoma in adults.
question was prioritised because it affects the early stages of the treatment pathway and could have significant clinical and cost...
NICE has developed a medtech innovation briefing (MIB) on LQD Spray for treating acute and chronic wounds .
Early value assessment (EVA) guidance on artificial intelligence (AI) technologies to aid contouring for radiotherapy treatment planning in people having external beam radiotherapy.
Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes (TA390)
Evidence-based recommendations on canagliflozin (Invokana), dapagliflozin (Forxiga) and empagliflozin (Jardiance) as options for treating type 2 diabetes in adults.